bromodeoxyuridine has been researched along with pd 123319 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guerra, MJ; Labandeira-Garcia, JL; Parga, JA; Quiroz, CR; Rodriguez-Pallares, J | 1 |
1 other study(ies) available for bromodeoxyuridine and pd 123319
| Article | Year |
|---|---|
Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors.
Topics: Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Apoptosis; Bromodeoxyuridine; Cell Count; Cell Differentiation; Cells, Cultured; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Interactions; Embryo, Mammalian; Glial Fibrillary Acidic Protein; Imidazoles; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Membrane Glycoproteins; Membrane Transport Proteins; Mesencephalon; Naphthyridines; Nerve Tissue Proteins; Neurons; Phosphopyruvate Hydratase; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Stem Cells; Tubulin; Tyrosine 3-Monooxygenase | 2004 |